-
1.发明申请LISTERIA ATTENUATED FOR ENTRY INTO NON-PHAGOCYTIC CELLS, VACCINES COMPRISING THE LISTERIA, AND METHODS OF USE THEREOF 有权被引入非糖代谢细胞的肠梗阻，包含肠炎的疫苗及其使用方法公开(公告)号：US20110201092A1
公开(公告)日：2011-08-18
申请号：US12748586
申请日：2010-03-29
IPC分类号： C12N1/20
CPC分类号： A61K39/07 , A61K2039/5154 , A61K2039/522 , A61K2039/523
摘要： The present invention provides Listeria that are attenuated for entry into non-phagocytic cells as well as a variety of methods of inducing immune responses involving administering compositions comprising the attenuated Listeria. Some of the attenuated Listeria are mutant Listeria that comprise at least one mutation in a gene encoding an invasin, such as an internalin. Some of the attenuated Listeria are further attenuated for cell-to-cell spread. Pharmaceutical compositions and vaccines useful in the methods of the invention are further provided. Methods of making and improving vaccines are also provided.
摘要翻译： 本发明提供减毒以进入非吞噬细胞的李斯特菌以及诱导涉及施用包含减毒李斯特菌的组合物的免疫应答的多种方法。 一些减毒李斯特氏菌是突变型李斯特菌，其在编码侵入素的基因（例如内含蛋白）中包含至少一个突变。 一些减毒的李斯特菌进一步减弱细胞到细胞的扩散。 还提供了可用于本发明方法的药物组合物和疫苗。 还提供了制备和改进疫苗的方法。
-
2.发明申请MODIFIED FREE-LIVING MICROBES, VACCINE COMPOSITIONS AND METHODS OF USE THEREOF 有权改性免费生活微生物，疫苗组合物及其使用方法公开(公告)号：US20100068230A1
公开(公告)日：2010-03-18
申请号：US10883599
申请日：2004-06-30
申请人： Thomas W. Dubensky, JR. , Dirk G. Brockstedt , John E. Hearst , David N. Cook , William S. Luckett, JR.
发明人： Thomas W. Dubensky, JR. , Dirk G. Brockstedt , John E. Hearst , David N. Cook , William S. Luckett, JR.
CPC分类号： A61K39/07 , A61K2039/5254 , A61K2039/5256 , Y02A50/401
摘要： Free-living microbes are provided in which the nucleic acid has been modified so that the microbe is attenuated for proliferation and/or which comprise genetic mutations that attenuate the ability of the microbe to repair its nucleic acid. Methods of using the modified microbes for the loading, activation, and/or maturation of antigen-presenting cells are also provided. Vaccine compositions comprising the modified microbes and/or the antigen-presenting cells and methods of using the vaccines are also provided. The microbes may be further modified to include heterologous antigens, such as tumor antigens or infectious disease antigens, for use as a vaccine against cancer or infectious diseases.
摘要翻译： 提供了自由活的微生物，其中已经修饰了核酸，使得微生物被减弱以用于增殖和/或包含减弱微生物修复其核酸的能力的遗传突变。 还提供了使用修饰的微生物来加载，激活和/或成熟抗原呈递细胞的方法。 还提供了包含修饰的微生物和/或抗原呈递细胞的疫苗组合物和使用疫苗的方法。 可以进一步修饰微生物以包括异源抗原，例如肿瘤抗原或感染性疾病抗原，用作抗癌或感染性疾病的疫苗。
-
3.发明申请COMPOSITIONS COMPRISING PRFA* MUTANT LISTERIA AND MEHTODS OF USE THEREOF 审中-公开包含PRFA *突变体肠梗阻的组合物及其使用的MEHTODE公开(公告)号：US20110287055A1
公开(公告)日：2011-11-24
申请号：US12993115
申请日：2009-05-18
申请人： Peter M. Lauer , Thomas W. Dubensky, JR. , Justin Skoble , Dirk G. Brockstedt , William Stanford Luckett, JR. , William Hanson
发明人： Peter M. Lauer , Thomas W. Dubensky, JR. , Justin Skoble , Dirk G. Brockstedt , William Stanford Luckett, JR. , William Hanson
CPC分类号： C12N15/74 , A61K39/0208 , A61K2039/522 , A61K2039/523 , Y02A50/412
摘要： The invention provides recombinant Listeria that constitutively express Prf A and comprise polynucleotides that encode polypeptides such as tumor or infectious agent antigens, operably linked to a PrfA responsive regulatory agent. Methods of using the Listeria, and compositions thereof, to induce or enhance an immune response and/or in the treatment of disease are provided. Methods of producing the bacteria are also provided.
摘要翻译： 本发明提供组成型表达Prf A的重组利斯特氏菌，并且包含与PrfA反应性调节剂可操作地连接的编码多肽例如肿瘤或感染因子抗原的多核苷酸。 提供了使用利斯特氏菌及其组合物诱导或增强免疫应答和/或治疗疾病的方法。 还提供了生产细菌的方法。
-
4.发明申请METHODS AND COMPOSITIONS USING LISTERIA FOR ENHANCING IMMUNOGENICITY BY PRIME BOOST 有权利用LISTERIA增强免疫原性的方法和组合公开(公告)号：US20100233212A1
公开(公告)日：2010-09-16
申请号：US12374288
申请日：2007-07-17
CPC分类号： A61K39/0011 , A61K2039/5152 , A61K2039/521 , A61K2039/522 , A61K2039/523 , A61K2039/53 , A61K2039/545 , C12N2799/022 , C12N2799/023 , Y02A50/412
摘要： Provided herein are prime-boost regimens and materials used therein. The prime-boost regimens enhance the immune response to a target antigen. The vaccines used for boost are comprised of recombinant attenuated metabolically active Listeria that encodes an expressible antigen that is cross-reactive with the target antigen. In some examples, the immune response is a cellular immune response.
摘要翻译： 本文提供的是初始加强方案和其中使用的材料。 初始 - 加强方案增强对靶抗原的免疫应答。 用于加强的疫苗由重组减毒的代谢活性利斯特氏菌组成，其编码与靶抗原交叉反应的可表达抗原。 在一些实例中，免疫应答是细胞免疫应答。
-
公开(公告)号：US20110245480A1
公开(公告)日：2011-10-06
申请号：US13099280
申请日：2011-05-02
IPC分类号： C07H21/00
CPC分类号： A61K39/0011 , A61K2039/522 , A61K2039/523 , C07K14/195 , C07K14/705 , C07K2319/00 , C12N15/74
摘要： The invention provides a bacterium containing a polynucleotide comprising a nucleic acid encoding a heterologous antigen, as well as fusion protein partners. Also provided are vectors for mediating site-specific recombination and vectors comprising removable antibiotic resistance genes.
摘要翻译： 本发明提供了含有包含编码异源抗原的核酸的多核苷酸以及融合蛋白质伴侣的细菌。 还提供了用于介导位点特异性重组的载体和包含可除去的抗生素抗性基因的载体。
-
公开(公告)号：US20120121643A1
公开(公告)日：2012-05-17
申请号：US11713765
申请日：2007-03-01
CPC分类号： C07K14/195 , A61K39/0011 , A61K2039/522 , A61K2039/523 , A61K2039/53 , C07K14/705 , C07K2319/00 , C12N15/74
摘要： The invention provides a bacterium containing a polynucleotide comprising a nucleic acid encoding a heterologous antigen, as well as fusion protein partners. Also provided are vectors for mediating site-specific recombination and vectors comprising removable antibiotic resistance genes.
摘要翻译： 本发明提供了含有包含编码异源抗原的核酸的多核苷酸以及融合蛋白质伴侣的细菌。 还提供了用于介导位点特异性重组的载体和包含可除去的抗生素抗性基因的载体。
-
7.发明申请RECOMBINANT ALPHAVIRUS-BASED VECTORS WITH REDUCED INHIBITION OF CELLULAR MACRO-MOLECULAR SYNTHESIS 审中-公开基于重组腺病毒的载体，具有减少细胞宏观分子合成的抑制作用公开(公告)号：US20100330121A1
公开(公告)日：2010-12-30
申请号：US12845516
申请日：2010-07-28
申请人： Thomas W. Dubensky, JR. , John M. Polo , Barbara A. Belli , Sergey A. Dryga , Sondra Schlessinger , Ilya Frolov
发明人： Thomas W. Dubensky, JR. , John M. Polo , Barbara A. Belli , Sergey A. Dryga , Sondra Schlessinger , Ilya Frolov
CPC分类号： C07K14/005 , A61K39/00 , A61K48/00 , C12N7/00 , C12N15/79 , C12N15/86 , C12N2770/36121 , C12N2770/36122 , C12N2770/36143 , C12N2770/36162 , C12N2830/005 , C12N2830/006 , C12N2830/42 , C12N2830/48 , C12N2840/20 , C12N2840/203 , C12N2840/44
摘要： Isolated nucleic acid molecules are disclosed, comprising an alphavirus nonstructural protein gene which, when operably incorporated into a recombinant alphavirus particle, eukaryotic layered vector initiation system, or RNA vector replicon, has a reduced level of vector-specific RNA synthesis, as compared to wild-type, and the same or greater level of proteins encoded by RNA transcribed from the viral junction region promoter, as compared to a wild-type recombinant alphavirus particle. Also disclosed are RNA vector replicons, alphavirus vector constructs, and eukaryotic layered vector initiation systems which contain the above-identified nucleic acid molecules.
摘要翻译： 公开了分离的核酸分子，其包含甲病毒非结构蛋白基因，当可操作地并入重组甲病毒颗粒中时，与野生型相比，真核分子载体启动系统或RNA载体复制子具有降低的载体特异性RNA合成水平 类型，以及与野生型重组甲病毒颗粒相比，从病毒连接区启动子转录的RNA编码的相同或更高水平的蛋白质。 还公开了RNA载体复制子，甲病毒载体构建体和含有上述核酸分子的真核分子载体启动系统。
-
公开(公告)号：US20120231526A1
公开(公告)日：2012-09-13
申请号：US13430920
申请日：2012-03-27
申请人： John M. Polo , Catherine Greer , Maria Calderon-Cacia , Daniel De La Vega, JR. , Thomas W. Dubensky, JR.
发明人： John M. Polo , Catherine Greer , Maria Calderon-Cacia , Daniel De La Vega, JR. , Thomas W. Dubensky, JR.
IPC分类号： C12N7/02
CPC分类号： C12N7/00 , A61K48/00 , C12N15/86 , C12N2770/36151 , C12Q1/6897 , C12Q1/701
摘要： Methods of production and purification for viruses and virus-derived vectors, including those related to alphaviruses, are disclosed. In one aspect, methods of purification that subject alphavirus replicon particle preparations to one or more steps of chromatographic purification, such as using an ion exchange resin, are provided. Also disclosed are methods of characterizing alphavirus replicon particles and utilizing these materials for vaccines and gene-based therapeutics
摘要翻译： 公开了病毒和病毒衍生载体的生产和纯化方法，包括与甲病毒相关的方法。 一方面，提供将甲病毒复制子颗粒制备物进行一步或多步色谱纯化的纯化方法，例如使用离子交换树脂。 还公开了表征甲病毒复制子颗粒并利用这些材料用于疫苗和基于基因的治疗剂的方法
-
9.发明申请公开(公告)号：US20120039932A1
公开(公告)日：2012-02-16
申请号：US13277900
申请日：2011-10-20
IPC分类号： A61K39/00 , A61P37/04 , A61P35/00 , A61P31/16 , A61P31/20 , A61P31/22 , A61P31/14 , C12N15/867 , A61P31/18
CPC分类号： C12N15/86 , A61K39/0011 , A61K2039/5256 , C12N7/00 , C12N2740/15022 , C12N2740/15043 , C12N2770/36145 , Y02A50/466
摘要： Lentiviral vector particles comprising a Sindbis virus E2 glycoprotein variant and a lentiviral vector genome comprising a sequence of interest are provided. A lentiviral vector particle comprising: (a) an envelope comprising a Sindbis virus E2 glycoprotein variant; and (b) a lentiviral vector genome comprising a sequence of interest; wherein the E2 glycoprotein variant facilitates infection of dendritic cells by the lentiviral vector particle, and wherein the E2 glycoprotein variant has reduced binding to heparan sulfate compared to a reference sequence (HR strain).
摘要翻译： 提供包含辛德毕斯病毒E2糖蛋白变体和包含感兴趣序列的慢病毒载体基因组的慢病毒载体颗粒。 一种慢病毒载体颗粒，包括：（a）包含辛德毕斯病毒E2糖蛋白变体的包膜; 和（b）包含感兴趣序列的慢病毒载体基因组; 其中E2糖蛋白变体便于慢病毒载体颗粒感染树突状细胞，并且其中E2糖蛋白变体与参考序列（HR应变）相比具有减少的与硫酸乙酰肝素的结合。
-
10.发明申请公开(公告)号：US20120328655A1
公开(公告)日：2012-12-27
申请号：US13441502
申请日：2012-04-06
IPC分类号： A61K39/00 , A61K39/12 , A61P37/04 , A61K39/002 , A61K39/245 , A61K39/39 , A61K39/02
CPC分类号： A61K39/245 , A61K39/0011 , A61K39/12 , A61K39/39 , A61K2039/53 , A61K2039/545 , A61K2039/55566 , A61K2039/55572 , A61K2039/70 , C12N2710/16634 , C12N2740/15034 , C12N2740/16043 , C12N2810/609
摘要： Compositions and methods are provided herein for improved dual immunization strategies that induce in a subject an immune response that includes a humoral immune response and cellular immune response, both CD4 and CD8 T lymphocyte immune responses, thereby providing a complete adaptive immune response to one or more antigens. The methods described are therefore useful for treating and/or preventing (i.e., reducing the likelihood or risk of occurrence) different diseases, disorders, and conditions such as cancers and infectious diseases for which induction of both a humoral immune response and cellular immune response is desired and beneficial.
摘要翻译： 本文提供的组合物和方法用于改善的双重免疫策略，其在受试者中诱导包括CD4和CD8 T淋巴细胞免疫应答的体液免疫应答和细胞免疫应答的免疫应答，从而为一种或多种 抗原。 因此，所描述的方法可用于治疗和/或预防（即，降低发生的可能性或风险）不同的疾病，病症和病症，例如诱导体液免疫应答和细胞免疫应答的癌症和感染性疾病 期望和有益。
-
-
-
-
-
-
-
-
-
搜索结果
19 条记录 (耗时 0.04 秒)
